Research Progress of Glycoprotein Antibodies

Glycoprotein antibodies which targeting glycans or oligosaccharides of glycoproteins are often also modified with glycosylation. Glycoprotein antibodies play an important role in the recognition of the immune system, while they are acting as significant biomarkers for clinical diagnosis and prognosis. However, the researches of glycoprotein antibodies are limited by the complexity of glycan chains and low affinity, leading to the difficulty in obtaining specific anti-glycan antibodies. Based on world-leading technologies and experienced scientific staff, Creative Biolabs has established an advanced Anti-Gly™ platform as well as launched comprehensive and one-stop Anti-Glycoprotein Antibody Development services. With years of experience in the discovery of anti-glycoprotein monoclonal antibodies (mAbs), we can offer high-quality customized services by adjusting protocols to meet even the most specific requirements.

Fig.1 Neoglycolipid-based microarrays. (Feizi, 2013)

Fig.1 Neoglycolipid-based microarrays are used
for carbohydrate recognition in the immune system.^{1, 2}

Introduction of Glycoprotein Antibodies

Glycans and glycoproteins are predominant surface components of cells such as erythrocytes, immune cells, and microorganisms. As such, they give rise to high levels of glycoprotein antibodies of all classes and are related to immune system activation. Moreover, Antibodies to glycoproteins have been shown to be effective markers for many diseases phenotype like inflammatory bowel disease and cancers.

Generally speaking, most carbohydrates are classified as T-cell independent antigens, which cannot recruit T-cell help and lead to a B-cell response lacking affinity maturation. As a result, the observed affinities of natural glycoprotein antibodies are typically lower than other antibodies. Therefore, it is important to develop specific glycoprotein antibodies with high affinities in vitro. After nearly a decade of development, we have established a glycoprotein antibodies development and screening platform.

Our Technologies in Glycoprotein Antibodies Research

Phage Display Technology

Phage display technology is a powerful tool to discover mAbs for therapeutic or diagnostic purposes which has been widely applied in the development of specific antibodies. Moreover, mRNA display, mammalian cell display, and yeast display technologies are generally accepted in the screening of glycoprotein antibodies.

Glycobiology Microarray

Glycobiology microarray provides a convenient, high throughput approach to examining carbohydrate-protein interactions, and has a significant impact on the field of specific glycoprotein antibodies development. Based on more than thousands of common carbohydrates in over 10 categories, we can detect glycoprotein antibodies with high affinity.

Hybridoma Technology

As one of the maturest methods in protein engineering, hybridoma technology has greatly increased the specificity of antibodies as well as permitted large-scale production of specific antibodies. With decades of development, we have established a comprehensive glycoprotein expression platform.

It is no doubt that Glycoprotein antibody has been advanced as a kind of promising therapeutic antibody in the field of novel drug development. If you are interested in our Glycoprotein Antibody Development services or have any related requirements, please feel free to contact us.